title: Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis.
abstract: OBJECTIVE
  Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non-alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non-alcoholic steatohepatitis (NASH) from simple steatosis (SS).
  
  
  METHODS
  We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high-throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined.
  
  
  RESULTS
  Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis.
  
  
  CONCLUSIONS
  We clearly demonstrated whole-serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.
authors.affiliation: Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Okayama.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yamasaki
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nouso
authors.forename: Koji
authors.initials: K
authors.lastname: Miyahara
authors.forename: Nozomu
authors.initials: N
authors.lastname: Wada
authors.forename: Chihiro
authors.initials: C
authors.lastname: Dohi
authors.forename: Yuki
authors.initials: Y
authors.lastname: Morimoto
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kinugasa
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Takeuchi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yasunaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Kuwaki
authors.forename: Hideki
authors.initials: H
authors.lastname: Onishi
authors.forename: Fusao
authors.initials: F
authors.lastname: Ikeda
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyake
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nakamura
authors.forename: Hidenori
authors.initials: H
authors.lastname: Shiraha
authors.forename: Akinobu
authors.initials: A
authors.lastname: Takaki
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: Maho
authors.initials: M
authors.lastname: Amano
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Nishimura
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D003937:Diagnosis, Differential; D005234:Fatty Liver / Q000175:diagnosis*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis*; D011134:Polysaccharides / Q000097:blood*; D011237:Predictive Value of Tests; D055815:Young Adult
chemical_list: D015415:Biomarkers; D011134:Polysaccharides
keywords: diagnosis; non-alcoholic steatohepatitis; serum glycan